-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
API is an important part of the pharmaceutical industry and one of the core directions of China's new pharmaceutical manufacturing
.
It is a key link in the upstream supply chain of the pharmaceutical industry chain .
In recent years, with the continuous accelerated development of the pharmaceutical industry, the size of China's API market has been continuously expanding
.
It is worth mentioning that, as the API market continues to improve due to the development of the pharmaceutical industry and is ushering in a rapid increase in volume, a large number of companies are also expanding their production capacity to further meet the demand for APIs in the pharmaceutical market
.
API companies have expanded production, forcing the pharmaceutical machinery industry to accelerate innovation and upgrading (Source: Pharmaceutical Network) Many API projects over 100 million yuan have started construction.
Recently, Haixiang Pharmaceutical issued an announcement saying that it plans to establish a wholly-owned subsidiary Yichang Haixiang Pharmaceutical Co.
, Ltd.
, a subsidiary, purchased approximately 500 acres of land use rights in Yaojiagang Chemical Park, Zhijiang City, Hubei Province, and invested in the construction of Hubei Pharmaceutical and Chemical Comprehensive Production Base Project
.
It is reported that the project is divided into two phases to build production lines of various raw materials, pharmaceutical intermediates and fine chemicals.
The total investment of the project is estimated to be about 2 billion yuan
.
Among them, the first phase of the project is planned to start construction in April 2022, with a construction period of 12 months, and it is planned to be officially put into operation in April 2023
.
On November 23, CRO giant Jiuzhou Pharmaceutical announced that it plans to acquire a 100% stake in Taihua Hangzhou held by Taihua Investment at an estimated transaction price of US$34 million (approximately RMB 217 million)
.
According to data, Taihua Hangzhou is an API manufacturing factory invested by the large international pharmaceutical company Teva Group in China, and it is mainly responsible for supplying Teva Group with products required for its business
.
The factory is located in Qiantang New District, Hangzhou, covering an area of 115 acres.
It has about 210 employees and the management team has more than 10 years of industry experience
.
After the completion of this transaction, Jiuzhou Pharmaceutical will also provide customized production services for Teva Group as agreed in the agreement
.
On November 18, the peptide API of Xingputai Biopharmaceutical Co.
, Ltd.
with a total investment of 1.
03 billion yuan also kicked off the construction of Taixing Economic Development Zone
.
It is understood that the Xingputai peptide API project was invested and constructed by Shanghai Shengpuzetai Pharmaceutical Technology Co.
, Ltd.
, with a total investment of 1.
03 billion yuan and an area of 120 acres.
.
According to the plan, the project is scheduled to be completed in December 2022.
After reaching production capacity, it is expected to achieve annual sales revenue of 3 billion yuan and taxation of 420 million yuan
.
In addition to the above companies, since the beginning of this year, Hendy Pharmaceuticals, Levi Pharmaceuticals, etc.
have also announced that they will spend huge amounts of money to build API projects
.
The industry believes that under the background of enterprises expanding production, it fully reflects the high prosperity of China's API industry
.
It is worth noting that, in this context, the prosperity of the pharmaceutical equipment industry is expected to increase accordingly
.
API companies are expanding production, and related equipment companies are accelerating their deployment.
The pharmaceutical sector is inseparable from the help of pharmaceutical equipment.
Therefore, as a large number of pharmaceutical companies invest in the construction of API production bases, the demand for API equipment is expected to continue to increase
.
In addition, the development of China's API industry is facing many challenges; for example, under the high pressure of a series of energy-saving and emission reduction policies, API companies are facing strict environmental protection supervision; and the requirements for API production capacity are continuously increasing, etc.
, all will fall.
Forcing raw drug companies to upgrade and renew related pharmaceutical equipment, generating more demand
.
It is understood that domestic drug production equipment category very rich, including fermentation tank, reaction tank, leaching and extraction systems, crystallizing tank, filtration equipment, drying equipment
.
According to the current development trend of the API industry, the industry believes that equipment manufacturers that deploy environmentally friendly, energy-saving, intelligent, and automated equipment in advance are expected to usher in more benefits
.
In fact, as far as the author knows, many domestic pharmaceutical equipment providers have already smelled the direction of industrial upgrading, and have already taken the lead in laying out on the new track, hoping to seize the market in the field
.
For example, Chutian Technology released two innovative overall solutions for aseptic products on November 19
.
According to reports, the overall solution is developed for the aseptic freeze-dried API market, which can realize the continuity of freeze-drying, discharging, crushing, mixing and sub-packaging processes, and the entire process is isolated, sealed, and automated, which can help API users to meet the green Low-carbon requirements to ensure the quality of pharmaceutical production
.
At the same time, due to the use of isolator technology to replace the traditional open manufacturing, it is also conducive to reducing the user's operation and maintenance costs, and reducing the impact of dust diffusion on the environment and personnel
.
Industry insiders said that the innovative advantages of this solution will be of great significance to the high-quality development of the API industry and the cost control of pharmaceutical companies
.
Conclusion In general, while the API industry and companies continue to develop, they are also forcing domestic API production equipment manufacturers to increase R&D investment, continue to obtain new breakthroughs in high-end areas, and promote better development of the API industry
.
The industry believes that from the current industry development trends and policy directions, the future development of high-end production equipment, energy-saving and environmental protection equipment, and smart equipment will become the main trends of the industry
.
.
It is a key link in the upstream supply chain of the pharmaceutical industry chain .
In recent years, with the continuous accelerated development of the pharmaceutical industry, the size of China's API market has been continuously expanding
.
It is worth mentioning that, as the API market continues to improve due to the development of the pharmaceutical industry and is ushering in a rapid increase in volume, a large number of companies are also expanding their production capacity to further meet the demand for APIs in the pharmaceutical market
.
API companies have expanded production, forcing the pharmaceutical machinery industry to accelerate innovation and upgrading (Source: Pharmaceutical Network) Many API projects over 100 million yuan have started construction.
Recently, Haixiang Pharmaceutical issued an announcement saying that it plans to establish a wholly-owned subsidiary Yichang Haixiang Pharmaceutical Co.
, Ltd.
, a subsidiary, purchased approximately 500 acres of land use rights in Yaojiagang Chemical Park, Zhijiang City, Hubei Province, and invested in the construction of Hubei Pharmaceutical and Chemical Comprehensive Production Base Project
.
It is reported that the project is divided into two phases to build production lines of various raw materials, pharmaceutical intermediates and fine chemicals.
The total investment of the project is estimated to be about 2 billion yuan
.
Among them, the first phase of the project is planned to start construction in April 2022, with a construction period of 12 months, and it is planned to be officially put into operation in April 2023
.
On November 23, CRO giant Jiuzhou Pharmaceutical announced that it plans to acquire a 100% stake in Taihua Hangzhou held by Taihua Investment at an estimated transaction price of US$34 million (approximately RMB 217 million)
.
According to data, Taihua Hangzhou is an API manufacturing factory invested by the large international pharmaceutical company Teva Group in China, and it is mainly responsible for supplying Teva Group with products required for its business
.
The factory is located in Qiantang New District, Hangzhou, covering an area of 115 acres.
It has about 210 employees and the management team has more than 10 years of industry experience
.
After the completion of this transaction, Jiuzhou Pharmaceutical will also provide customized production services for Teva Group as agreed in the agreement
.
On November 18, the peptide API of Xingputai Biopharmaceutical Co.
, Ltd.
with a total investment of 1.
03 billion yuan also kicked off the construction of Taixing Economic Development Zone
.
It is understood that the Xingputai peptide API project was invested and constructed by Shanghai Shengpuzetai Pharmaceutical Technology Co.
, Ltd.
, with a total investment of 1.
03 billion yuan and an area of 120 acres.
.
According to the plan, the project is scheduled to be completed in December 2022.
After reaching production capacity, it is expected to achieve annual sales revenue of 3 billion yuan and taxation of 420 million yuan
.
In addition to the above companies, since the beginning of this year, Hendy Pharmaceuticals, Levi Pharmaceuticals, etc.
have also announced that they will spend huge amounts of money to build API projects
.
The industry believes that under the background of enterprises expanding production, it fully reflects the high prosperity of China's API industry
.
It is worth noting that, in this context, the prosperity of the pharmaceutical equipment industry is expected to increase accordingly
.
API companies are expanding production, and related equipment companies are accelerating their deployment.
The pharmaceutical sector is inseparable from the help of pharmaceutical equipment.
Therefore, as a large number of pharmaceutical companies invest in the construction of API production bases, the demand for API equipment is expected to continue to increase
.
In addition, the development of China's API industry is facing many challenges; for example, under the high pressure of a series of energy-saving and emission reduction policies, API companies are facing strict environmental protection supervision; and the requirements for API production capacity are continuously increasing, etc.
, all will fall.
Forcing raw drug companies to upgrade and renew related pharmaceutical equipment, generating more demand
.
It is understood that domestic drug production equipment category very rich, including fermentation tank, reaction tank, leaching and extraction systems, crystallizing tank, filtration equipment, drying equipment
.
According to the current development trend of the API industry, the industry believes that equipment manufacturers that deploy environmentally friendly, energy-saving, intelligent, and automated equipment in advance are expected to usher in more benefits
.
In fact, as far as the author knows, many domestic pharmaceutical equipment providers have already smelled the direction of industrial upgrading, and have already taken the lead in laying out on the new track, hoping to seize the market in the field
.
For example, Chutian Technology released two innovative overall solutions for aseptic products on November 19
.
According to reports, the overall solution is developed for the aseptic freeze-dried API market, which can realize the continuity of freeze-drying, discharging, crushing, mixing and sub-packaging processes, and the entire process is isolated, sealed, and automated, which can help API users to meet the green Low-carbon requirements to ensure the quality of pharmaceutical production
.
At the same time, due to the use of isolator technology to replace the traditional open manufacturing, it is also conducive to reducing the user's operation and maintenance costs, and reducing the impact of dust diffusion on the environment and personnel
.
Industry insiders said that the innovative advantages of this solution will be of great significance to the high-quality development of the API industry and the cost control of pharmaceutical companies
.
Conclusion In general, while the API industry and companies continue to develop, they are also forcing domestic API production equipment manufacturers to increase R&D investment, continue to obtain new breakthroughs in high-end areas, and promote better development of the API industry
.
The industry believes that from the current industry development trends and policy directions, the future development of high-end production equipment, energy-saving and environmental protection equipment, and smart equipment will become the main trends of the industry
.
